

**IMPORTANT:**

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited, Hong Kong Securities Clearing Company Limited and the Securities and Futures Commission (the "**SFC**") take no responsibility for the contents of this Announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement.

SFC authorisation is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

**This Announcement is important and requires your immediate attention. If you are in any doubt about the contents of this Announcement, you should seek professional advice. Investment involves risks which may result in significant loss as there is no guarantee on investment returns.**

The Manager accepts full responsibility for the accuracy of the information contained in this Announcement and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, there are no other facts the omission of which would make any statement misleading.

**ChinaAMC Global ETF Series (the "Trust")**

*(a Hong Kong umbrella unit trust authorised under  
Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)*

**ChinaAMC Hang Seng Hong Kong Biotech Index ETF**

*HKD Counter Stock Code: 3069  
RMB Counter Stock Code: 83069  
USD Counter Stock Code: 9069*

(the "**Sub-Fund**")

**ANNOUNCEMENT**

**Indicative Net Asset Value of the RMB traded Units of the Sub-Fund**

Dear Unitholders,

Unless otherwise stated, capitalised terms in this Announcement have the same meanings as defined in the prospectus of the Sub-Fund.

Reference is made to the announcement dated 19 December 2023 and issued by China Asset Management (Hong Kong) Limited, the manager of the Trust and the Sub-Fund (the "**Manager**"), relating to, among other things, the addition of new RMB counter to the Listed Class of Units of the Sub-Fund (the "**Announcement**"). As set out in the Announcement, the Manager has been granted approval by the SEHK for the Listed Class of Units to be available for trading on the SEHK and deposit, clearing and settlement in CCASS under a Multi-Counter arrangement with the addition of a RMB counter from 19 January 2024.

The Manager hereby announces the indicative net asset value ("**NAV**") of the Units trading in the RMB counter of the Sub-Fund as of 18 January 2024 at 4:10 p.m.:

<b>Stock Code</b>	83069
<b>Short Stock Name</b>	CAM HSBIOTECH-R
<b>Trading Currency</b>	RMB
<b>NAV per Unit in Trading Currency as of 18 January 2024</b>	RMB 8.37

The latest indicative NAV will be used on 19 January 2024 during pre-opening session (“**POS**”) as the POS reference price.

If you have any queries or require further information in relation to any aspect of this Announcement, please contact the Manager at 37/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong or on +852 3406 8686 during normal office hours.

**China Asset Management (Hong Kong) Limited**  
as Manager of the Trust and the Sub-Fund

**18 January 2024**